Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Therapy for myositis

C V Oddis1

  • 1Department of Medicine, University of Pittsburgh School of Medicine, PA 15261.

Current Opinion in Rheumatology
|November 1, 1993
PubMed
Summary
This summary is machine-generated.

Corticosteroids are common for inflammatory myopathy but have side effects. Alternative therapies like immunosuppressants and newer agents show promise, though plasma exchange and leukapheresis lack proven benefit.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Anti-hydroxy-3-methylglutaryl-coenzyme A reductase (anti-HMGCR) antibody in necrotizing myopathy: treatment outcomes, cancer risk, and role of autoantibody level.

Scandinavian journal of rheumatology·2019
Same author

Update on the pharmacological treatment of adult myositis.

Journal of internal medicine·2016
Same author

Autoantibodies to a 140-kd protein in juvenile dermatomyositis are associated with calcinosis.

Arthritis and rheumatism·2009
Same author

Sensory Neuropathy With Sjögren's Syndrome, Thymoma, and Hypogammaglobulinemia.

Journal of clinical neuromuscular disease·2008
Same author

Myositis-specific and -associated autoantibodies: a review from the clinical perspective.

Journal of clinical neuromuscular disease·2008
Same author

The protein tyrosine phosphatase N22 gene is associated with juvenile and adult idiopathic inflammatory myopathy independent of the HLA 8.1 haplotype in British Caucasian patients.

Arthritis and rheumatism·2008
Same journal

New approaches to the management of cutaneous lupus.

Current opinion in rheumatology·2026
Same journal

"Updates in chronic nonbacterial osteomyelitis: emerging insights across the age spectrum".

Current opinion in rheumatology·2026
Same journal

Difficult-to-treat, complex-to-manage, treatment-refractory spondyloarthritis: semantics or substance?

Current opinion in rheumatology·2026
Same journal

Update on IgA nephropathy: implications for treatment in IgA vasculitis: a guide for rheumatologists.

Current opinion in rheumatology·2026
Same journal

Polyarticular juvenile idiopathic arthritis: insights from genetic studies on disease risk and pathogenesis.

Current opinion in rheumatology·2026
Same journal

Immune dysregulation in children with Down syndrome: clinical implications and emerging therapies.

Current opinion in rheumatology·2026
See all related articles

Area of Science:

  • Rheumatology and Immunology
  • Neuromuscular Disorders

Background:

  • Inflammatory myopathy management presents significant challenges.
  • Corticosteroids are the primary treatment but often show limited efficacy and considerable side effects.
  • The need for alternative therapeutic strategies is therefore substantial.

Purpose of the Study:

  • To review current and emerging therapeutic options for inflammatory myopathy.
  • To evaluate the efficacy and role of non-corticosteroid treatments.
  • To discuss the impact of autoantibody identification on treatment strategies.

Main Methods:

  • Review of existing literature on inflammatory myopathy treatments.
  • Analysis of studies investigating corticosteroids, immunosuppressive drugs, and immune-modulating agents.

Related Experiment Videos

  • Inclusion of data from randomized controlled trials where available, such as for plasma exchange.

    • Main Results:

    • Non-corticosteroid agents including methotrexate, azathioprine, chlorambucil, and cyclophosphamide offer benefits.
    • Cyclosporine shows encouraging results in recent studies.
    • Intravenous immunoglobulin has demonstrated efficacy in some myositis patients.
    • Plasma exchange and leukapheresis did not show benefit in a key randomized trial.

    Conclusions:

    • Combination therapy, incorporating corticosteroids with immunosuppressants or immune modulators, is increasingly utilized.
    • Identification of specific autoantibodies aids in classifying disease severity and guiding aggressive treatment.
    • Further research into novel agents is warranted for refractory cases of inflammatory myopathy.